Abstract:
The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which consists in administering such a composition or such an extract.
Abstract:
The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth thereof and/or slow the loss thereof. According to said method, a cosmetic composition including at least one C7 sugar, or derivative from esterification of said sugar, is administered. The present invention finally relates to a method for cosmetic care of hair and/or eyelashes and/or nails.
Abstract:
The present invention relates to the use of a lupin peptide extract to prevent loss of skin firmness or to increase the firmness of skin. Advantageously, the lupin peptide extract can prevent the appearance of cellulite and/or reduce skin cellulite.
Abstract:
The invention relates to in vitro methods for testing formulations or active ingredients for preventing the harmful effects of UV on children's skin, in particular children aged three or less. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the harmful effects of UV on the skin of children aged three or less, using a skin model specifically capable of reproducing the characteristics of the skin of children of this age.
Abstract:
The present invention relates to a method for determining the isotropy of the skin surface of a subject, and hence the degree of maturation of the said skin surface, by examining various parameters reflecting the cell organization. Methods for identifying active agents, raw materials and formulation are also provided.
Abstract:
The present invention relates to the use of a peptide and glycoside extract of Schizandra fruit as a cutaneous neurosensory agent, for improving the response of the cutaneous neurosensory system, in particular for: —improving cutaneous innervation in the basal state, —combatting age-related loss of cutaneous innervation in the basal state, advantageously for preventing loss of the cutaneous sensitivity and/or combatting thinning of the epidermis, and/or—improving cutaneous perception of the environment, more particularly for combatting burns, extreme cold and/or pain.
Abstract:
The invention relates to an extract of aerial parts of Maca rich in polyphenols, and also to a composition comprising such an extract and, where appropriate, a suitable excipient. The invention also relates to a process for extracting an extract of aerial parts of Maca rich in polyphenols, and also to the extract that can be obtained by means of said process. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths and/or for use thereof in preventing and/or treating vascular disorders. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which comprises the administration of such a composition or of such an extract.
Abstract:
The invention relates to a cosmetic or dermatological composition containing a polyphenol-enriched extract of Vitex Negundo, typically a root extract obtained using a PAT plant milking®process. The invention further relates to a composition of this kind for use in the prevention or treatment of disorders and diseases affecting the skin, mucous membranes or skin appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of extrinsic or intrinsic skin aging. Lastly, the invention relates to a cosmetic care method for the skin, skin appendages or mucous membranes, with a view to improving the condition or appearance thereof, said method consisting in administering such a composition or such an extract.
Abstract:
The present invention relates to a method for determining the relief of the skin surface of a subject, and hence the degree of maturation of the said skin surface. Methods for identifying active agents, raw materials and formulation are also provided.
Abstract:
A first subject of the invention is a skin model characterized in that it comprises keratinocytes capable of overexpressing filaggrin. A second subject of the invention is a method for evaluating the in vitro activity of a formulation or of at least one active agent on the healing of nipple skin and/or on the reduction of nipple skin inflammation, characterized in that said method comprises at least the following steps: a) bringing said active agent or said formulation into contact with a skin model comprising keratinocytes overexpressing filaggrin and also comprising a lesion; b) measuring the level of production of at least one biological marker in the nipple skin model of step a), characterized in that said biological marker can be chosen from lactate dehydrogenase (LDH), TNFα, filaggrin, TGFβ1 and β1 integrin; c) comparing the level of production of at least one biological marker obtained in step b) with a reference level of production; evaluating the efficacy of said active agent or of said formulation according to the comparison of step c).